• Moderna Inc MRNA.OQ reported a quarterly adjusted loss of $2.52​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-3.07. The mean expectation of eighteen analysts for the quarter was for a loss of $3.14 per share. Wall Street expected results to range from $-3.60 to $-2.86 per share.

• Revenue fell 35.3% to $108.00 million from a year ago; analysts expected $106.20 million.

• Moderna Inc's reported EPS for the quarter was a loss of $2.52​.

• The company reported a quarterly loss of $971 million.

• Moderna Inc shares had risen by 0.7% this quarter and lost 31.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.7% in the last three months.​

• In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy," 18 "hold" and 4 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

• Wall Street's median 12-month price target for Moderna Inc is $35.00

This summary was machine generated from LSEG data May 1 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)